tiprankstipranks
Trending News
More News >
SUNWELS Co.,Ltd. (JP:9229)
:9229
Japanese Market

SUNWELS Co.,Ltd. (9229) AI Stock Analysis

Compare
0 Followers

Top Page

JP

SUNWELS Co.,Ltd.

(9229)

Rating:49Neutral
Price Target:
¥596.00
▼(-0.67%Downside)
The company's financial performance is the most significant factor, with strong revenue growth overshadowed by concerns in profitability and cash flow management. Technical analysis indicates moderate strength, yet valuation reflects significant profitability challenges. These factors combine to produce a below-average overall stock score.

SUNWELS Co.,Ltd. (9229) vs. iShares MSCI Japan ETF (EWJ)

SUNWELS Co.,Ltd. Business Overview & Revenue Model

Company Descriptionnull
How the Company Makes Moneynull

SUNWELS Co.,Ltd. Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownTTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue26.33B21.36B13.72B8.42B5.40B4.38B
Gross Profit6.38B6.42B3.75B2.11B1.38B1.23B
EBITDA2.37B4.35B1.93B819.00M562.83M405.01M
Net Income454.00M2.03B784.00M255.71M241.42M148.00M
Balance Sheet
Total Assets40.45B31.52B19.21B9.02B4.79B3.47B
Cash, Cash Equivalents and Short-Term Investments6.59B3.31B2.61B814.76M496.36M1.35B
Total Debt22.82B20.11B11.20B6.60B3.03B2.04B
Total Liabilities31.03B24.38B13.84B8.15B4.09B2.98B
Stockholders Equity9.42B7.14B5.37B864.74M693.47M487.00M
Cash Flow
Free Cash Flow0.00-2.94B-741.00M-78.18M-392.99M-209.21M
Operating Cash Flow0.002.56B1.14B378.19M201.03M313.13M
Investing Cash Flow0.00-5.66B-2.04B-633.05M-648.06M-551.00M
Financing Cash Flow0.003.80B2.70B573.26M489.42M-818.72M

SUNWELS Co.,Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price600.00
Price Trends
50DMA
572.22
Positive
100DMA
579.00
Positive
200DMA
846.11
Negative
Market Momentum
MACD
5.79
Positive
RSI
56.91
Neutral
STOCH
44.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9229, the sentiment is Positive. The current price of 600 is below the 20-day moving average (MA) of 603.10, above the 50-day MA of 572.22, and below the 200-day MA of 846.11, indicating a neutral trend. The MACD of 5.79 indicates Positive momentum. The RSI at 56.91 is Neutral, neither overbought nor oversold. The STOCH value of 44.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9229.

SUNWELS Co.,Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥18.98B12.47
3.95%4.15%-25.67%
68
Neutral
¥8.77B20.08
10.60%15.70%
66
Neutral
¥9.80B13.31
1.49%20.50%62.39%
63
Neutral
¥5.95B2.91
3.25%0.91%856.87%
63
Neutral
¥8.78B15.87
1.44%21.97%-20.94%
49
Neutral
¥22.29B159.73
2.84%29.51%-175.29%
46
Neutral
C$198.48M-3.49-23.22%2.62%21.07%-1.26%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:9229
SUNWELS Co.,Ltd.
633.00
-1,795.31
-73.93%
JP:2374
Saint-Care Holding Corp.
752.00
-79.86
-9.60%
JP:6059
Uchiyama Holdings Co., Ltd.
309.00
-26.76
-7.97%
JP:6557
AIAI Group Corporation
1,326.00
803.50
153.78%
JP:7061
Japan Hospice Holdings Inc.
1,032.00
-380.49
-26.94%
JP:7133
HYUGA PRIMARY CARE Co.,Ltd.
1,351.00
-253.94
-15.82%

SUNWELS Co.,Ltd. Corporate Events

Sunwels Co., Ltd. Announces FY March 2025 Financial Highlights and Healthcare Initiatives
May 15, 2025

Sunwels Co., Ltd. is focusing on addressing societal challenges in healthcare and caregiving by establishing specialized facilities like the ‘PD House’ for Parkinson’s disease, aiming for a sustainable society. The company announced its financial highlights for the fiscal year ending March 2025, emphasizing its commitment to healthcare innovation and sustainability, which may enhance its industry positioning and stakeholder value.

SUNWELS Co.,Ltd. Reports Increased Sales but Declining Profits for FY 2025
May 15, 2025

SUNWELS Co.,Ltd. reported its non-consolidated financial results for the year ending March 31, 2025, showing a significant increase in net sales by 31.8% to 26,496 million yen. However, the company faced a substantial decline in profitability, with operating profit falling by 51.0% and ordinary profit decreasing by 77.4%, resulting in a net loss of 925 million yen. The financial results indicate challenges in maintaining profitability despite increased sales, and the company has decided not to issue dividends for the year. This financial performance could impact its market positioning and stakeholder confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025